Sector Focus | Core Technology: Development and manufacturing of innovative cell culture supplements, specifically Human Platelet Lysate (HPL) for cell therapy research, regenerative medicine and biopharmaceutical manufacturing.
Mission Statement | Company Vision: PL BioScience catalyzes the research & development of cell therapy and regenerative medicine through advanced cell culture media. As Europe’s only HPL specialist, it maintains its leading position in Europe while actively building a strong market presence in Asia and the U.S.

Products | Services:

• ELAREM™ Platform: Broad range of xeno-free, donor-based HPL products.
• ELAREM™ Ultimate-FD PLUS: The only gamma-irradiated, GMP-grade HPL with IP protection.
• PL Synergy Bundle: Pre-validated platform for potent, reproducible cell growth in advanced media.

Target Market | Application Area: Our HPL technology replaces animal-derived serum with a human- derived alternative, providing the consistency and regulatory confidence necessary to deliver life-saving therapies faster. We serve companies, academic institutions, and clinical developers who need safe, ethical, consistent cell culture supplements supporting human cell growth for research and therapeutic use.
Unique Selling Proposition (USP): One platform, one supplier — from first experiment to commercial scale — sets ELAREM™ apart. A portfolio of purpose-built HPL solutions, taking customers from research through GMP-level clinical manufacture on a single, validated platform, ELAREM™ eliminates reformulation risk and regulatory burden.